Amifostine
A cytoprotective prodrug that is converted to an active metabolite in normal tissues to scavenge free radicals and reduce the toxicity of radiation and certain chemotherapy drugs like cisplatin, protecting healthy cells while having limited activity in tumor tissue. It is used to reduce kidney toxicity from cisplatin and decrease dry mouth from head and neck radiation therapy.
Peso molecular
214,2300 g/mol
LogP
-4,50
TPSA
121,00 Ų
Regla de cinco de Lipinski
Cumple
Áreas terapéuticas
Mecanismo de acción
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Estructura 2D
Cite this structure
Embed this structure
SMILES
NCCCNCCSP(=O)(O)O
InChI
InChI=1S/C5H15N2O3PS/c6-2-1-3-7-4-5-12-11(8,9)10/h7H,1-6H2,(H2,8,9,10)
Molecular Formula
C5H15N2O3PS
HBD / HBA
4 / 6
Enlaces Rotables
7
Átomos Pesados
12
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Preguntas frecuentes
A cytoprotective prodrug that is converted to an active metabolite in normal tissues to scavenge free radicals and reduce the toxicity of radiation and certain chemotherapy drugs like cisplatin, protecting healthy cells while having limited activity in tumor tissue. It is used to reduce kidney toxicity from cisplatin and decrease dry mouth from head and neck radiation therapy.
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Yes, Amifostine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1006. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 2141. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="amifostine"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/amifostine/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/amifostine/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/amifostine/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="amifostine"></drugfyi-drug>